SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Jansson Per Anders)
 

Sökning: WFRF:(Jansson Per Anders) > Effects of dapaglif...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006377naa a2200697 4500
001oai:gup.ub.gu.se/269679
003SwePub
008240528s2018 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-364901
0247 a https://gup.ub.gu.se/publication/2696792 URI
0247 a https://doi.org/10.1007/s00125-018-4675-22 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3649012 URI
040 a (SwePub)gud (SwePub)uu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Eriksson, Jan W.u Uppsala universitet,Klinisk diabetologi och metabolism4 aut0 (Swepub:uu)janer909
2451 0a Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
264 c 2018-07-03
264 1b Springer Science and Business Media LLC,c 2018
520 a Aims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 (n-3) carboxylic acids (OM-3CA). individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin (n = 21). 4 g OM3-CA (n = 20), a combination of both (n = 22) or placebo (n = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). Results Participants had a mean age of 65.5 years (SD 5.9), BMI 31.2 kg/m(2) (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, -15%; dapagliflozin, -13%; OM-3CA + dapagliflozin, -21%. Only the combination treatment reduced liver PDFF (p = 0.046) and total liver fat volume (relative change, -24%,p = 0.037) in comparison with placebo. There was an interaction between the PNPLA31148M polymorphism and change in liver PDFF in the active treatment groups (p = 0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transfcrase (gamma-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in gamma-GT correlated with changes in liver PDFF (rho = 0.53, p = 0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. Conclusions/interpretation Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
653 a Dapagliflozin
653 a Docosahexaenoic acid
653 a Eicosapentaenoic acid
653 a Liver steatosis
653 a Non-alcoholic fatty liver
653 a growth-factor 21
653 a insulin sensitivity
653 a controlled-trial
653 a fish-oil
653 a steatohepatitis
653 a glucose
653 a oxidation
653 a pnpla3
653 a resistance
653 a adaptation
653 a Endocrinology & Metabolism
653 a Dapagliflozin
7001 a Lundkvist, Peru Uppsala universitet,Klinisk diabetologi och metabolism4 aut0 (Swepub:uu)perlu970
7001 a Jansson, Per-Anders,d 1961u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden.4 aut0 (Swepub:gu)xjansp
7001 a Johansson, L.u Antaros Med AB, Gothenburg, Sweden.4 aut
7001 a Kvarnstrom, M.u AstraZeneca Gothenburg, Gothenburg, Sweden.4 aut
7001 a Moris, L.u Karolinska Univ Hosp, ICarolinska Trial Alliance, Stockholm, Sweden.4 aut
7001 a Miliotis, T.u AstraZeneca Gothenburg, Gothenburg, Sweden.4 aut
7001 a Forsberg, G. B.u AstraZeneca Gothenburg, Gothenburg, Sweden.4 aut
7001 a Risérus, Ulf,d 1967-u Uppsala universitet,Klinisk nutrition och metabolism4 aut0 (Swepub:uu)ulfriser
7001 a Lind, Larsu Uppsala universitet,Institutionen för medicinska vetenskaper,Klinisk nutrition och metabolism4 aut0 (Swepub:uu)larslind
7001 a Oscarsson, J.u AstraZeneca Gothenburg, Gothenburg, Sweden.4 aut
7102 a Uppsala universitetb Klinisk diabetologi och metabolism4 org
7730 t Diabetologiad : Springer Science and Business Media LLCg 61:9, s. 1923-1934q 61:9<1923-1934x 0012-186Xx 1432-0428
8564 u https://link.springer.com/content/pdf/10.1007/s00125-018-4675-2.pdf
8564 u https://doi.org/10.1007/s00125-018-4675-2y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1262619/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://gup.ub.gu.se/publication/269679
8564 8u https://doi.org/10.1007/s00125-018-4675-2
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-364901

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy